[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.108.121. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 3,883
Citations 0
Editorial
September 2016

Notice of Retraction: Sato Y, et al. Risedronate Sodium Therapy for Prevention of Hip Fracture in Men 65 Years or Older After Stroke. Arch Intern Med. 2005;165(15):1743-1748.

Author Affiliations
  • 1Editor in Chief, JAMA
  • 2Editor, JAMA Internal Medicine
  • 3Department of Medicine, University of California, San Francisco
JAMA Intern Med. 2016;176(9):1256. doi:10.1001/jamainternmed.2016.3771

The following article, Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med. 2005;165(15):1743-1748,1 has been retracted due to acknowledgment of scientific misconduct resulting in concerns about data integrity and inappropriate assignment of authorship.

Back to top
Article Information

Corresponding Author: Rita F. Redberg, MD, MSc, University of California, San Francisco, 505 Parnassus Ave, M1180, San Francisco, CA 94143 (redberg@medicine.ucsf.edu).

Published Online: June 3, 2016. doi:10.1001/jamainternmed.2016.3771.

Conflict of Interest Disclosures: None reported.

References
1.
Sato  Y, Iwamoto  J, Kanoko  T, Satoh  K.  Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med. 2005;165(15):1743-1748.
PubMedArticle
×